Alternative splicing (AS) is prevalent in cancer, generating an extensive but largely
unexplored repertoire of novel immunotherapy targets. We describe I soform peptides from …

Immunotherapy has emerged as a crucial strategy to combat cancer by “reprogramming” a
patient's own immune system. Although immunotherapy is typically reserved for patients with …

Simple Summary Alternative splicing is one of the most fabulous and important mechanism
in the cell. Alternative splicing is capable of generating many proteins from a single gene …

Cancer neoantigens have shown great potential in immunotherapy, while current software
focuses on identifying neoantigens which are derived from SNVs, indels or gene fusions …

In cancer, non-synonymous DNA base changes alter protein sequence and produce
neoantigens that are detected by the immune system. For immune detection, neoantigens …

Immunotherapies are yielding effective treatments for several previously untreatable
cancers. Still, the identification of suitable antigens specific to the tumour that can be targets …

Personalization of cancer immunotherapies such as therapeutic vaccines and adoptive T-
cell therapy may benefit from efficient identification and targeting of patient-specific …

Alternative pre-mRNA splicing (AS) provides the potential to produce diversity at RNA and
protein levels. Disruptions in the regulation of pre-mRNA splicing can lead to diseases. With …

Cancer-related epitopes can engage the immune system against tumor cells, thus exploring
epitopes derived from non-coding regions is emerging as a fascinating field in cancer …

The acquisition of somatic mutations is the most common event in cancer. Neoantigens
expressed from genes with mutations acquired during carcinogenesis can be tumor-specific …